Skip to content
Business websites
Business websites
J&J Innovative Medicine
J&J MedTech
J&J Innovative Medicine
J&J MedTech
Location
Language
English
Choose your country or region
China
中国人
France
Français
India
English
Japan
日本
Switzerland
Deutsch
English
Français
US
English
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Our culture of inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our history
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Inclusion
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Menu
Latest news
Innovation
Caring & giving
Personal stories
Health & wellness
Our Company
Discover J&J
Our Credo
Our Leadership
Code of Business Conduct
Corporate reports
Our culture of inclusion
ESG Policies & Positions
Innovation at J&J
Uniting science and technology
Office of the Chief Medical Officer
Veterans, military & military families
Innovative Medicine
MedTech
Our societal impact
Global Health Equity
Global environmental sustainability
Suppliers
Responsible supply base
Supplier-enabled innovation
Supplier resources
Our history
Careers
Search jobs
Life at J&J
Employee benefits
Professional development
Employee stories
Inclusion
Our teams
Oncology
Immunology
Data science
Market access
Medical affairs
Innovation, development and partnerships
MedTech and surgical robotics
Locations
North America
EMEA
Asia Pacific
Latin America
Student opportunities
Internships
Co-ops
Full-time student jobs
Leadership and development opportunities
How we hire
Application tips
Hiring programs
Hiring FAQs
Join our Global Talent Hub
Investors
Pharmaceutical pipeline
ESG resources
Investor fact sheet
Media Center
Press releases
Search Query
Submit Search
Clear
Dictate search request
Search Results
No Results
Recently Viewed
Listening...
Sorry, I don't understand. Please try again
Show Search
Home
/
Media Center
/
Press releases
Press releases
Press Releases
Search Query
Submit Search
Clear
Dictate search request
Listening...
Sorry, I don't understand. Please try again
2,154 Results
Date
All Dates (2154)
Past 30 days (22)
2023 (139)
2022 (124)
2021 (184)
2020 (109)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (2154)
Corporate (147)
Financial (303)
Innovative Medicine (963)
Leadership (20)
Medical technologies (293)
Research (41)
2,154 results
Filters
Date
All Dates (2154)
Past 30 days (22)
2023 (139)
2022 (124)
2021 (184)
2020 (109)
2019 (130)
2018 (166)
2017 (194)
2016 (125)
Topic
All (2154)
Corporate (147)
Financial (303)
Innovative Medicine (963)
Leadership (20)
Medical technologies (293)
Research (41)
Sort By:
Newest
Newest
Relevance
Oldest
June 17, 2025
Johnson & Johnson seeks U.S. FDA approval of STELARA® (ustekinumab) for the treatment of pediatric Crohn’s disease
Supported by 52-week data from the Phase 3 UNITI-Jr study, submission aims to expand STELARA® indication to treat children two years of age and older
Read more
June 17, 2025
Johnson & Johnson Launches New TECNIS Odyssey Next-Generation Intraocular Lens in Europe, the Middle East, and Canada Offering Cataract Patients Precise Vision at Every Distance in Any Lighting*†‡1,6
The new full visual range*1 IOL enables 93% of patients to become free from glasses at all distances.**2 *** With best-in-class image contrast and low-light performance,#~3,4,5 TECNIS Odyssey IOL expands the Johnson & Johnson portfolio of advanced Presbyopia Correction IOLs. TECNIS Odyssey IOL enables surgeons to deliver consistent and reliable patient outcomes.∫7,15
Read more
June 15, 2025
Investigational combination of first-in-class bispecifics TALVEY® and TECVAYLI® shows deep and durable responses in heavily pretreated multiple myeloma patients with extramedullary disease
Results from the Phase 2 RedirecTT-1 study demonstrate deep responses with 78.9 percent overall response rate through dual targeting of GPRC5D and BCMA Data signal potential of novel, off-the-shelf approach in patients with extramedullary disease who face significant unmet needs
Read more
June 13, 2025
Johnson & Johnson’s dual-targeting CAR T-cell therapy shows encouraging first results in large B-cell lymphoma
Phase 1b study suggests a promising safety profile and highlights the potential of a novel dual-targeting CD19/CD20 CAR T in patients with relapsed or refractory disease 75-80% complete response rate among evaluable patients at the recommended Phase 2 dose
Read more
June 12, 2025
New results for Johnson & Johnson’s bleximenib demonstrate promising antileukemic activity in combination with venetoclax and azacitidine for acute myeloid leukemia
Bleximenib, an investigational selective menin inhibitor, shows potential as combination therapy for the treatment of relapsed or refractory AML and newly diagnosed, intensive chemo-ineligible AML Phase 1b data show low rate of differentiation syndrome and no cardiac safety signal of QTc prolongation
Read more
June 12, 2025
Significant efficacy benefit of IMBRUVICA® (ibrutinib) plus venetoclax versus acalabrutinib plus venetoclax in frontline treatment of patients with chronic lymphocytic leukaemia suggested by indirect treatment comparison
Cross-study findings indicate significant clinical benefit of frontline fixed-duration ibrutinib plus venetoclax with improved likelihood of undetectable minimal residual disease and progression-free survival versus acalabrutinib plus venetoclax1 Phase 2 CAPTIVATE long-term follow-up data further supports sustained efficacy and safety profile of fixed-duration ibrutinib plus venetoclax treatment in patients receiving frontline treatment for chronic lymphocytic leukaemia2
Read more
June 11, 2025
New data show TREMFYA® (guselkumab) is the only IL-23 inhibitor proven to significantly inhibit progression of joint structural damage in active psoriatic arthritis
TREMFYA ® demonstrated two and a half times greater ability to inhibit joint structural damage versus placebo in the Phase 3b APEX study More than 40% of TREMFYA®-treated patients across both dose groups achieved ACR50 at Week 24 Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis
Read more
June 10, 2025
Johnson & Johnson Elects Daniel Pinto, President, JPMorganChase to its Board of Directors
Read more
June 10, 2025
Johnson & Johnson Launches the ETHICON™ 4000 Stapler for Elevated Surgical Experience and the Most Secure Staple Line Yet1
The stapling system features ETHICON™ 3D Reloads with proprietary 3D Stapling Technology and enhanced Gripping Surface Technology to manage tissue complexities and reduced potential leaks and bleeds at the staple line2I New ETHICON advanced stapling technology to be harnessed for future use exclusively on the OTTAVA™ Robotic Surgical System ETHICON 4000 Stapler and ETHICON™ 3D Reloads will be showcased at the American Society for Metabolic and Bariatric Surgery Annual Meeting on June 15-19, 2025
Read more
June 3, 2025
DARZALEX FASPRO® (daratumumab and hyaluronidase-fihj)-based regimen shows 95 percent progression-free survival at four years in transplant-eligible, newly diagnosed patients with multiple myeloma who achieved sustained MRD negativity
More than half of patients maintained minimal residual disease (MRD) negativity (10-5) with DARZALEX FASPRO® for 24 months or longer in the Phase 3 PERSEUS study Data from Phase 3 CEPHEUS study show 60 percent overall MRD negativity (10−5) and improved PFS with DARZALEX FASPRO® in transplant-ineligible newly diagnosed patients
Read more
Load More